Physician profile
Long Le
NPI 1588010870
$885.14
in general payments reported to CMS, 2019-2025
11 companies · $478 in 2025
The $478 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.89 · 2024: $389 · 2025: $478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $867.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $867.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $310.45 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $206.71 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $125.00 | 2024 | Epclusa |
| Ardelyx, INC. | $75.40 | 2025 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $32.25 | 2025 | Iqirvo |
| Takeda Pharmaceuticals U.S.A., INC. | $31.53 | 2025 | Entyvio |
| Qol Medical, LLC | $30.57 | 2024 | Sucraid |
| Pfizer INC. | $23.51 | 2025 | |
| Amgen INC. | $17.89 | 2019 | |
| Janssen Biotech, INC. | $17.39 | 2025 | Tremfya |
| Madrigal Pharmaceuticals | $14.44 | 2025 | Rezdiffra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Long Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.